S
Singlera Genomics
A developer of 'liquid biopsy' analysis reagents and software, focusing on determing methylation haplotypes across many thousands of genomic locations in cell-free DNA
About Singlera Genomics
Singlera Genomics is a company that specializes in liquid biopsy for non-invasive early cancer detection. The company has developed proprietary technologies for analyzing cell-free DNA (cfDNA) methylation, which allows for the early detection of various types of cancer.
Read full description
Their product portfolio includes assays for different cancers, such as the PDACatch for pancreatic cancer, which has received Breakthrough Device Designation from the FDA, and ColonAiQ for colorectal cancer, which has been approved by the NMPA in China. The company's business model revolves around the development and commercialization of these diagnostic tests. They serve high-risk individuals and the broader healthcare market, providing tools for cancer screening, diagnosis, and monitoring. Singlera Genomics operates globally with locations in the US and China and generates revenue through the sale of its diagnostic products and services.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- San Diego, United States
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 69.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, DNA, Genetics and genomics, Non-Invasive medical devices and treatments, Spinout, Genome Engineering, Biotech and Pharma, medical testing
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2024 | $14M | $55M | Yangzhou Longchuan Holding Group · Guojin Group | ↗ |
| SERIES BOther financing | Jun 2022 | $45M | $764M | Sansure Biotech · Galaxy Yuanhui Investment · Forstone Capital · Shengxiang Bio | ↗ |
Growth signals
Latest recorded traffic for Singlera Genomics is 320 monthly website visits, up 146.2% over the last three months. Singlera Genomics's team grew 3.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A21 investors entered at this stage
Lilly Asia Ventures
CD Capital
Green Pine Capital- PVProsperico Ventures
CICC- FMFTZ Fund Management
Proxima Ventures
Wuxi Capital- HGHuamei Group
Detong Capital- LMLinden Asset Management
- FIFudan University Ningbo Research Institute
FutureX Capital
Sansure Biotech
Galaxy Yuanhui Investment
Forstone Capital- SBShengxiang Bio
- GFGandao Fund
- QFQiandao Fund
- FCFengshi Capital
- BSBai Shide
Series B and later3 investors entered at this stage
- JIJunci Investment
- YGYangzhou Longchuan Holding Group
- GGGuojin Group
Other known investors2 additional known investors
Johns Hopkins University
University of California, San Diego
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Singlera Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Singlera Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.